This study is testing a new drug called CHS-114 for people with advanced solid tumors, which are types of cancers that grow in body tissues. The study is in Phase 1, meaning it's the first time the drug is being tested in humans to see how safe it is and how the body handles it. CHS-114 is a monoclonal antibody, a special protein designed to target and attack cancer cells by focusing on a specific part called CCR8. The study has three parts, with one part testing CHS-114 alone and others testing it with another drug, toripalimab.

• The study will involve different groups, with about 81 participants in total.
• Participants must be over 18 and have advanced cancer that has not improved with standard treatments.
• Participants should not have received similar treatments before and must be in stable health to participate.

Before joining, patients should discuss potential risks and whether the study requirements fit their needs with their doctor. Participants will need to follow specific health guidelines and visit the study site for check-ups. The goal is to find the right dose and understand the effects of CHS-114 on cancer cells.